Clinical Research Published: Dr. David Michelin

Congratulations to David Michelin, MD, who recently co-authored the following clinical journal article in JCO Precision Oncology:

Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Highlights:

• Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets.
• Results of a cohort of patients with solid tumors with BRAF alterations treated with regorafenib are reported.
• Regorafenib did not meet prespecified criteria to declare a signal of activity in patients with solid tumors with BRAF alterations.

Dr. Michelin practices at Munson Healthcare Gynecologic Oncology. 

Questions? Contact Dr. David Michelin.